BUZZ-Australia's Immuron rises on positive results for Travelan Phase 2 study

Reuters

Jan 14, 2025

** Shares of Immuron rise as much as 16.3% to A$0.10, set for their strongest session since April 10, 2024, if gains hold

** The biopharmaceutical co hits highest level since early October

** Co submits clinical study report for its recently completed Phase 2 study of Travelan to the U.S. FDA

** Travelan is one of co's flagship products aimed at reducing the likelihood of contracting traveler's diarrhoea

** Study implies that Travelan aids the reduction of pathological diarrhoea-causing bacteria over time

** About 1.8 mln shares change hands, 28.6 times compared with the 30-day average volume of 63,415 shares

** Stock rose 2.6% in 2024

(Reporting by Manasi Dasa Sundeep in Bengaluru)

((Manasi.DasaSundeep@ThomsonReuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503560075"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503560075\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503560075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 10:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503560075","market":null,"top_or_hot":-1,"title":"BUZZ-Australia's Immuron rises on positive results for Travelan Phase 2 study","media":"Reuters","content":"<html><body><p>** Shares of Immuron    rise as much as 16.3% to A$0.10, set for their strongest session since April 10, 2024, if gains hold</p><p>   ** The biopharmaceutical co hits highest level since early October</p><p>   ** Co submits clinical study report for its recently completed Phase 2 study of Travelan to the U.S. FDA</p><p>   ** Travelan is one of co's flagship products aimed at reducing the likelihood of contracting traveler's diarrhoea</p><p>   ** Study implies that Travelan aids the reduction of pathological diarrhoea-causing bacteria over time</p><p>   ** About 1.8 mln shares change hands, 28.6 times compared with the 30-day average volume of 63,415 shares</p><p>   ** Stock rose 2.6% in 2024</p><p> (Reporting by Manasi Dasa Sundeep in Bengaluru)</p><p>((Manasi.DasaSundeep@ThomsonReuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Immuron rises on positive results for Travelan Phase 2 study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Immuron rises on positive results for Travelan Phase 2 study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-14 10:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>** Shares of Immuron    rise as much as 16.3% to A$0.10, set for their strongest session since April 10, 2024, if gains hold</p><p>   ** The biopharmaceutical co hits highest level since early October</p><p>   ** Co submits clinical study report for its recently completed Phase 2 study of Travelan to the U.S. FDA</p><p>   ** Travelan is one of co's flagship products aimed at reducing the likelihood of contracting traveler's diarrhoea</p><p>   ** Study implies that Travelan aids the reduction of pathological diarrhoea-causing bacteria over time</p><p>   ** About 1.8 mln shares change hands, 28.6 times compared with the 30-day average volume of 63,415 shares</p><p>   ** Stock rose 2.6% in 2024</p><p> (Reporting by Manasi Dasa Sundeep in Bengaluru)</p><p>((Manasi.DasaSundeep@ThomsonReuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XKO.AU","symbol_name":"标普/澳交所 300指数","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2503560075","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503560075","pubTimestamp":1736823060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of Immuron    rise as much as 16.3% to A$0.10, set for their strongest session since April 10, 2024, if gains hold   ** The biopharmaceutical co hits highest level since early October   ** Co submits clinical study report for its recently completed Phase 2 study of Travelan to the U.S. FDA   ** Travelan is one of co's flagship products aimed at reducing the likelihood of contracting traveler's diarrhoea   ** Study implies that Travelan aids the reduction of pathological diarrhoea-causing bacteria over time   ** About 1.8 mln shares change hands, 28.6 times compared with the 30-day average volume of 63,415 shares   ** Stock rose 2.6% in 2024 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XKO.AU":"标普/澳交所 300指数","IMC.AU":"IMMURON LTD","XJO.AU":"标普/澳交所 200指数","BK7067":"生物科技","BK7508":"医药生物股","XAO.AU":"标普/澳交所 普通股指数"},"translate_title":"BUZZ-澳大利亚Immuron因Travelan 2期研究取得积极结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XJO.AU":1,"IMC.AU":0.9,"XAO.AU":1,"XKO.AU":1},"content_text":"** Shares of Immuron    rise as much as 16.3% to A$0.10, set for their strongest session since April 10, 2024, if gains hold   ** The biopharmaceutical co hits highest level since early October   ** Co submits clinical study report for its recently completed Phase 2 study of Travelan to the U.S. FDA   ** Travelan is one of co's flagship products aimed at reducing the likelihood of contracting traveler's diarrhoea   ** Study implies that Travelan aids the reduction of pathological diarrhoea-causing bacteria over time   ** About 1.8 mln shares change hands, 28.6 times compared with the 30-day average volume of 63,415 shares   ** Stock rose 2.6% in 2024 (Reporting by Manasi Dasa Sundeep in Bengaluru)((Manasi.DasaSundeep@ThomsonReuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}